

Research Study: Utilizing Neuroimaging to Categorize Patients with Alzheimer's Disease and Healthy Individuals

Section 1: Objectives and Context

Section 1.1: Overview

1.1.1 The Challenge Posed by Alzheimer's Disease

The field of neurology and the medical community are confronted with a significant problem in the form of Alzheimer's disease (AD). The aforementioned is a progressive neurological disorder that exhibits a deteriorating trajectory and has a widespread impact on a substantial number of individuals worldwide, mostly among the older population. Alzheimer's disease (AD) is characterized by the gradual decline in cognitive functions, including memory, thinking, and problem-solving ability. The individuals impacted by this ailment, together with their families and healthcare organizations, experience a significant burden as the severity of the condition progresses.

1.1.2 The Significance of Prompt Identification

Early diagnosis is a crucial element in effectively managing Alzheimer's disease (AD). The prompt identification and prompt management of the condition might potentially hinder its progression and improve the overall well-being of those affected by it, assuming that an early diagnosis is established. However, during its first phases, Alzheimer's disease (AD) is notoriously hard to diagnose and often requires invasive procedures or advanced imaging techniques.

1.1.3 The Role of Machine Learning and Brain Imaging in Cognitive Science

The primary objective of this research is to facilitate the early detection of Alzheimer's disease (AD) by the use of machine learning techniques in combination with medical imaging, namely T1-weighted MRI brain scans. The objective is to establish a technique that is capable of being scaled, has high accuracy, and is non-intrusive in order to ascertain if an individual's brain imaging exhibits indications that they could be susceptible to Alzheimer's disease (AD). This study aligns with the larger goal of improving early diagnostic and therapy options for Alzheimer's disease (AD).

Section 1.2: Rationale/Reasoning

1.2.1 Improving Diagnostic Proficiency

The impetus for this endeavor stems from the pressing need to enhance diagnostic proficiency in the field of Alzheimer's disease. Contemporary diagnostic methodologies often rely on clinical assessments and cognitive examinations, which may not provide timely indications of early-stage

disease. The use of brain imaging data offers a potential avenue for enhanced precision and unbiased diagnosis.

1.2.2 Prompt Intervention and Improved Outcomes

The early management of Alzheimer's disease (AD) may include several interventions, such as pharmacological treatment, adjustments to one's lifestyle, or engagement in clinical trials investigating innovative therapeutic approaches. These therapeutic interventions have the potential to delay cognitive decline, mitigate the progression of the illness, and improve the overall quality of life for patients.

1.2.3 Utilizing Multidisciplinary Knowledge

The effort leverages the collective expertise of professionals in the fields of machine learning and medical imaging. The objective of our study is to foster a collaborative relationship across these fields with the aim of facilitating the development of improved diagnostic instruments for neurodegenerative diseases, namely Alzheimer's disease (AD). In order to effectively tackle the intricate challenges associated with brain image processing and classification, it is essential to foster collaboration across the many disciplines involved.

Section 1.3 The Multifactorial Contribution

1.3.1 Utilizing the Findings from Lab 1

The study utilizes the knowledge acquired during the first laboratory session, which focused on examining the preprocessing techniques used to brain pictures. The acquisition of this information is essential in order to properly configure the MRI brain scans for the purpose of extracting features. The methodology used in our study involves many preprocessing processes, including tissue segmentation, image registration, and skull stripping.

1.3.2 Expanding on Lab 2 Understanding

Furthermore, this research builds upon the findings acquired during the second laboratory session, which focused on the examination of the classification of medical photographs. In Lab 2, we examined the importance of feature engineering, model evaluation, and appropriate selection of classification methods. The categorization of participants into those with Alzheimer's disease (AD) and those without (normal controls) is determined by our technique, which is based on these principles.

1.3.3 Addressing Complex Challenges

The prediction of Alzheimer's disease (AD) involves the consideration of intricate matters that need the incorporation of diverse sets of information obtained from both Lab 1 and Lab 2. One of the challenges in this domain is effectively managing diverse brain imaging data, ensuring accurate extraction of features, and developing dependable classification algorithms. The objective of our study is to develop a comprehensive framework that addresses these difficulties from a holistic standpoint, integrating insights from other labs.

Section 2: Contributions of Team Members

Our team consisted of three individuals, each assuming responsibility for a certain domain of the project.

Contributions of Team Members

Name of member	Content of contribution	Rate of contribution
Yuyan Wang	Initial environment setting, Skull stripping, Tissue segment, Measurement	33%
Utkarsh Vashisht	Registration and Voxel measurement	33%
IoTou Lei	SVM process for data, Measurement	33%

The successful management of the project's many duties was achieved via collaborative efforts and the use of our individual strengths, enabling us to collectively attain our objective.

Section 3: Methodology

Our process incorporates the following essential phases:

Section 3.1: Feature Extraction

3.1.1 Expanding the Scope of Feature Extraction

In this work, feature extraction surpasses the standard approach of estimating the volume of grey matter within a specific region of interest (ROI). The aim of this study is to obtain feature representations for each participant by extracting data from the first ninety regions of interest (ROIs) in the Automated Anatomical Labeling (AAL) atlas. This addition facilitates the enhancement of the discriminative power of the classification model and permits the extraction of a more diverse range of information from brain images.

3.1.2 Key Sub-Tasks

The feature extraction method encompasses many essential subtasks or processes.

Skull-stripping: Removing non-brain tissue and isolating the brain region of interest from the photos which we had been given.

Tissue Segmentation: Identifying and segmenting different tissue types, including grey matter, white matter, and cerebrospinal fluid (CSF). We used FAST command for this.

Image Registration: Aligning brain images to a common template or space to ensure was very important for consistent analysis and it was carried out in two steps which were affine and deformable registration respectively.

Measurement: Quantifying relevant features, such as grey matter volumes, within specified ROIs.

3.1.3 Importance of Comprehensive Feature Extraction

In order to get meaningful patterns and information from brain scans, it is important to conduct comprehensive feature extraction. The objective of our study is to enhance the feature set of our classification model in order to improve its ability to differentiate between patients with Alzheimer's disease (AD) and those without the condition. This was achieved by extending our feature extraction process to include several regions of interest (ROIs).

Section 3.2: Feature Normalization

Feature normalization is a crucial preprocessing step in machine learning applications, especially when dealing with data that exhibit varying sizes or units. To ensure the uniformity of the features obtained from brain scans prior to their use in our Support Vector Machine (SVM) classifier, we implemented feature normalization as a technique in our study.

3.2.1 The Underlying Motivations for Feature Normalization (why should we do it?)

Different characteristics might have different ranges of values, which is why it is required to normalize the features. In the present context, it is plausible that there may be substantial variations in grey matter volumes seen across distinct areas of interest (ROIs) within brain scans throughout measurement. The magnitudes of various features may be attributed to variations in the volumes of certain regions of interest (ROIs).

3.2.2 The Process of Feature Normalization

The feature normalization technique consisted of two primary steps.

In the context of statistical analysis, the concept of centering mean refers to the process of subtracting the mean value of a variable from each individual data point within that variable

3.2.2.1 Centering Mean

The mean centering technique involves subtracting the average value of each feature across all training samples from each individual feature value. When doing this task, the data is normalized to have a mean of zero. In the realm of mathematics, with respect to each individual attribute.

Mean centering is a technique that ensures each feature has a mean of zero. This approach serves to mitigate the influence of features with larger values on the learning process.

3.2.2.2 Scaling with Unit Variance

The features were standardized by scaling them to have a variance of one after being centered around the mean. In this procedure, the scaling of each feature value is achieved by dividing it by its corresponding standard deviation.

By normalizing the data to have unit variance, it may be ensured that the variance of each characteristic is approximately equal to one. The importance of this step cannot be overstated, since Support Vector Machines (SVM) and other machine learning algorithms exhibit sensitivity to the dimensions of input features. To ensure that no one feature had a disproportionate impact, we used a scaling technique known as unit variance, which equalized the significance of all characteristics for the SVM classifier.

Section 3.3: Classification

In Section 3.3 of this report we go into the classification aspect, whereby individuals were categorized into two distinct groups: normal controls and patients with Alzheimer's disease (AD). This classification was achieved via the use of Support Vector Machines (SVM).

Support Vector Machines (SVMs) are a widely used machine learning algorithm.

Support Vector Machines (SVM) is a powerful supervised machine learning methodology that may be effectively used for both regression and classification tasks. In this work, we used support vector machines (SVM) for binary classification to determine if an individual had symptoms of Alzheimer's disease (AD) or served as a control group, based on the feature vectors obtained.

3.3.2 Overview of the Support Vector Machine (SVM) Procedure

The SVM classification process includes many essential steps, which are as follows:

3.3.2.1 Training

The process of generating feature vectors included using the normalized feature vectors obtained from the training dataset, which consisted of labeled instances of both patients with Alzheimer's disease (AD) and normal controls.

In the process of model training, the SVM method utilizes the feature vectors of individuals diagnosed with Alzheimer's disease (AD) and those from a control group without the disease. These feature vectors serve as input for the algorithm, which then learns to construct a decision boundary, sometimes referred to as a hyperplane. The margin, which refers to the distance between the nearest data points (support vectors) of both classes and the hyperplane, is the objective of optimization.

3.3.2.2 Testing

The test dataset, consisting of subjects for whom the prediction of AD status was desired, was used to apply the trained SVM model.

Feature Vector Preparation: The feature vectors of the test participants were obtained and then extracted.

Classification involves using the feature vectors of test participants to aid the SVM model in predicting the class labels to which they belong, namely AD patient or normal control.

Section 4: Results from the feature extraction tasks which were

Results from the feature extraction tasks which were *Skull-stripping: Tissue Segmentation: ,Image Registration and Measurement:*

The following screenshots/images are taken from train directory.

The results of the scripts which we ran in one place (train directory)–

Name	Type	Compressed size	Password pr...	Size	Ratio	Date modified
90ROI	File folder					05-10-2023 05:06
aal	File folder					05-10-2023 05:06
brain	File folder					05-10-2023 07:49
csv	File folder					05-10-2023 13:24
Greymatter	File folder					05-10-2023 08:09
ROIs	File folder					05-10-2023 05:06
segmentation	File folder					04-10-2023 19:41
AD01-AD10_data	Comma Separated Values So...	6 KB	No	11 KB	48%	05-10-2023 10:47
AD11-AD20_data	Comma Separated Values So...	6 KB	No	11 KB	48%	05-10-2023 12:27
NC01-NC10_data	Comma Separated Values So...	3 KB	No	11 KB	76%	05-10-2023 13:05
NC11-NC20_data	Comma Separated Values So...	3 KB	No	11 KB	76%	05-10-2023 13:23

The results of the brain segmentation-

Name	Type	Compressed size	Password pr...	Size	Ratio	Date modified
<input type="checkbox"/> AD_01.nii.gz_brain_seg_1.nii.gz	GZ File	313 KB	No	347 KB	10%	25-09-2023 05:07
<input type="checkbox"/> AD_02.nii.gz_brain_seg_1.nii.gz	GZ File	223 KB	No	256 KB	14%	25-09-2023 05:10
<input type="checkbox"/> AD_03.nii.gz_brain_seg_1.nii.gz	GZ File	210 KB	No	243 KB	14%	25-09-2023 05:13
<input type="checkbox"/> AD_04.nii.gz_brain_seg_1.nii.gz	GZ File	247 KB	No	281 KB	13%	25-09-2023 05:16
<input type="checkbox"/> AD_05.nii.gz_brain_seg_1.nii.gz	GZ File	183 KB	No	216 KB	16%	25-09-2023 05:18
<input type="checkbox"/> AD_06.nii.gz_brain_seg_1.nii.gz	GZ File	171 KB	No	204 KB	17%	25-09-2023 05:21
<input type="checkbox"/> AD_07.nii.gz_brain_seg_1.nii.gz	GZ File	195 KB	No	229 KB	15%	25-09-2023 05:24
<input type="checkbox"/> AD_08.nii.gz_brain_seg_1.nii.gz	GZ File	194 KB	No	229 KB	16%	25-09-2023 05:26
<input type="checkbox"/> AD_09.nii.gz_brain_seg_1.nii.gz	GZ File	204 KB	No	237 KB	15%	25-09-2023 05:29
<input type="checkbox"/> AD_10.nii.gz_brain_seg_1.nii.gz	GZ File	267 KB	No	303 KB	13%	25-09-2023 05:32
<input type="checkbox"/> AD_11.nii.gz_brain_seg_1.nii.gz	GZ File	239 KB	No	275 KB	14%	25-09-2023 05:35
<input type="checkbox"/> AD_12.nii.gz_brain_seg_1.nii.gz	GZ File	235 KB	No	271 KB	14%	25-09-2023 05:38
<input type="checkbox"/> AD_13.nii.gz_brain_seg_1.nii.gz	GZ File	221 KB	No	256 KB	14%	25-09-2023 05:40
<input type="checkbox"/> AD_14.nii.gz_brain_seg_1.nii.gz	GZ File	234 KB	No	266 KB	13%	25-09-2023 05:43
<input type="checkbox"/> AD_15.nii.gz_brain_seg_1.nii.gz	GZ File	236 KB	No	269 KB	13%	25-09-2023 05:46
<input type="checkbox"/> AD_16.nii.gz_brain_seg_1.nii.gz	GZ File	207 KB	No	241 KB	15%	25-09-2023 05:49
<input type="checkbox"/> AD_17.nii.gz_brain_seg_1.nii.gz	GZ File	212 KB	No	245 KB	14%	25-09-2023 05:52
<input type="checkbox"/> AD_18.nii.gz_brain_seg_1.nii.gz	GZ File	281 KB	No	317 KB	12%	25-09-2023 05:55
<input type="checkbox"/> AD_19.nii.gz_brain_seg_1.nii.gz	GZ File	294 KB	No	331 KB	12%	25-09-2023 05:58
<input type="checkbox"/> AD_20.nii.gz_brain_seg_1.nii.gz	GZ File	243 KB	No	278 KB	13%	25-09-2023 06:01
<input type="checkbox"/> NC_01.nii.gz_brain_seg_1.nii.gz	GZ File	216 KB	No	252 KB	15%	25-09-2023 06:04
<input type="checkbox"/> NC_02.nii.gz_brain_seg_1.nii.gz	GZ File	232 KB	No	268 KB	14%	25-09-2023 06:07
<input type="checkbox"/> NC_03.nii.gz_brain_seg_1.nii.gz	GZ File	277 KB	No	314 KB	12%	25-09-2023 06:10
<input type="checkbox"/> NC_04.nii.gz_brain_seg_1.nii.gz	GZ File	248 KB	No	286 KB	14%	25-09-2023 06:14
<input type="checkbox"/> NC_05.nii.gz_brain_seg_1.nii.gz	GZ File	230 KB	No	266 KB	14%	25-09-2023 06:17
<input type="checkbox"/> NC_06.nii.gz_brain_seg_1.nii.gz	GZ File	244 KB	No	281 KB	14%	25-09-2023 06:20
<input type="checkbox"/> NC_07.nii.gz_brain_seg_1.nii.gz	GZ File	283 KB	No	320 KB	12%	25-09-2023 06:24
<input type="checkbox"/> NC_08.nii.gz_brain_seg_1.nii.gz	GZ File	289 KB	No	325 KB	12%	25-09-2023 06:27
<input type="checkbox"/> NC_09.nii.gz_brain_seg_1.nii.gz	GZ File	261 KB	No	298 KB	13%	25-09-2023 06:31
<input type="checkbox"/> NC_10.nii.gz_brain_seg_1.nii.gz	GZ File	238 KB	No	275 KB	14%	25-09-2023 06:34
<input type="checkbox"/> NC_11.nii.gz_brain_seg_1.nii.gz	GZ File	276 KB	No	314 KB	13%	25-09-2023 06:38
<input type="checkbox"/> NC_12.nii.gz_brain_seg_1.nii.gz	GZ File	251 KB	No	288 KB	13%	25-09-2023 06:41
<input type="checkbox"/> NC_13.nii.gz_brain_seg_1.nii.gz	GZ File	249 KB	No	286 KB	13%	25-09-2023 06:44
<input type="checkbox"/> NC_14.nii.gz_brain_seg_1.nii.gz	GZ File	276 KB	No	314 KB	13%	25-09-2023 06:48

The results of the 90 ROIs per patient –

1	File folder	05-10-2023 05:43
2	File folder	05-10-2023 05:45
3	File folder	05-10-2023 05:47
4	File folder	05-10-2023 05:48
5	File folder	05-10-2023 05:50
6	File folder	05-10-2023 05:51
7	File folder	05-10-2023 05:53
8	File folder	05-10-2023 05:55
9	File folder	05-10-2023 05:57
10	File folder	05-10-2023 05:59
11	File folder	05-10-2023 06:01
12	File folder	05-10-2023 06:02
13	File folder	05-10-2023 06:04
14	File folder	05-10-2023 06:05
15	File folder	05-10-2023 06:06
16	File folder	05-10-2023 06:08
17	File folder	05-10-2023 06:09
18	File folder	05-10-2023 06:11
19	File folder	05-10-2023 06:12
20	File folder	05-10-2023 06:14
21	File folder	05-10-2023 06:15
22	File folder	05-10-2023 06:17
23	File folder	05-10-2023 06:18
24	File folder	05-10-2023 06:19
25	File folder	05-10-2023 06:20
26	File folder	05-10-2023 06:21
27	File folder	05-10-2023 06:22
28	File folder	05-10-2023 06:23
29	File folder	05-10-2023 06:26
30	File folder	05-10-2023 06:27
31	File folder	05-10-2023 06:28
32	File folder	05-10-2023 06:30
33	File folder	05-10-2023 06:31
34	File folder	05-10-2023 06:33

Name	Type	Compressed size	Password pr...	Size	Ratio	Date modified
7	File folder					05-10-2023 05:53
8	File folder					05-10-2023 05:55
9	File folder					05-10-2023 05:57
10	File folder					05-10-2023 05:59
11	File folder					05-10-2023 06:01
12	File folder					05-10-2023 06:02
13	File folder					05-10-2023 06:04
14	File folder					05-10-2023 06:05
15	File folder					05-10-2023 06:06
16	File folder					05-10-2023 06:08
17	File folder					05-10-2023 06:09
18	File folder					05-10-2023 06:11
19	File folder					05-10-2023 06:12
20	File folder					05-10-2023 06:14
21	File folder					05-10-2023 06:15
22	File folder					05-10-2023 06:17
23	File folder					05-10-2023 06:18
24	File folder					05-10-2023 06:19
25	File folder					05-10-2023 06:20
26	File folder					05-10-2023 06:21
27	File folder					05-10-2023 06:22
28	File folder					05-10-2023 06:23
29	File folder					05-10-2023 06:26
30	File folder					05-10-2023 06:27
31	File folder					05-10-2023 06:28
32	File folder					05-10-2023 06:30
33	File folder					05-10-2023 06:31
34	File folder					05-10-2023 06:33
35	File folder					05-10-2023 06:34
36	File folder					05-10-2023 06:35
37	File folder					05-10-2023 06:36
38	File folder					05-10-2023 06:36
39	File folder					05-10-2023 06:37
40	File folder					05-10-2023 06:38

Total 40 patients so 40 folders.

Opening folder 1 just as example –

AD_01.nii.gz_brain'_aal.nii.gz'.nii	NII File	242 KB	No	10,625 KB	98%	03-10-2023 19:27
AD_01.nii.gz_brain'_aal.nii.gz'.nii1.nii.gz	GZ File	7 KB	No	47 KB	87%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii2.nii.gz	GZ File	8 KB	No	48 KB	85%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii3.nii.gz	GZ File	8 KB	No	48 KB	85%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii4.nii.gz	GZ File	8 KB	No	49 KB	85%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii5.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii6.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii7.nii.gz	GZ File	8 KB	No	48 KB	85%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii8.nii.gz	GZ File	9 KB	No	50 KB	83%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii9.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii10.nii.gz	GZ File	4 KB	No	45 KB	93%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii11.nii.gz	GZ File	4 KB	No	45 KB	93%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii12.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii13.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii14.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii15.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii16.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii17.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii18.nii.gz	GZ File	4 KB	No	45 KB	92%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii19.nii.gz	GZ File	6 KB	No	47 KB	89%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii20.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii21.nii.gz	GZ File	2 KB	No	43 KB	96%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii22.nii.gz	GZ File	3 KB	No	43 KB	96%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii23.nii.gz	GZ File	6 KB	No	47 KB	88%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii24.nii.gz	GZ File	5 KB	No	45 KB	91%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii25.nii.gz	GZ File	3 KB	No	44 KB	94%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii26.nii.gz	GZ File	3 KB	No	44 KB	95%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii27.nii.gz	GZ File	3 KB	No	44 KB	94%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii28.nii.gz	GZ File	3 KB	No	44 KB	94%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii29.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii30.nii.gz	GZ File	5 KB	No	46 KB	90%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii31.nii.gz	GZ File	5 KB	No	46 KB	91%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii32.nii.gz	GZ File	3 KB	No	44 KB	94%	05-10-2023 05:42
AD_01.nii.gz_brain'_aal.nii.gz'.nii33.nii.gz	GZ File	5 KB	No	47 KB	89%	05-10-2023 05:42

The greymatter images being made due to the script/filecode measurement-

AD_01_greymatter.nii.gz	GZ File	2,295 KB	No	2,332 KB	2%	05-10-2023 08:00
AD_02_greymatter.nii.gz	GZ File	1,921 KB	No	1,963 KB	3%	05-10-2023 08:00
AD_03_greymatter.nii.gz	GZ File	1,619 KB	No	1,661 KB	3%	05-10-2023 08:00
AD_04_greymatter.nii.gz	GZ File	1,739 KB	No	1,779 KB	3%	05-10-2023 08:00
AD_05_greymatter.nii.gz	GZ File	1,486 KB	No	1,526 KB	3%	05-10-2023 08:00
AD_06_greymatter.nii.gz	GZ File	1,147 KB	No	1,187 KB	4%	05-10-2023 08:00
AD_07_greymatter.nii.gz	GZ File	1,598 KB	No	1,639 KB	3%	05-10-2023 08:00
AD_08_greymatter.nii.gz	GZ File	1,521 KB	No	1,565 KB	3%	05-10-2023 08:00
AD_09_greymatter.nii.gz	GZ File	1,573 KB	No	1,613 KB	3%	05-10-2023 08:00
AD_10_greymatter.nii.gz	GZ File	2,169 KB	No	2,211 KB	2%	05-10-2023 08:01
AD_11_greymatter.nii.gz	GZ File	1,641 KB	No	1,682 KB	3%	05-10-2023 08:01
AD_12_greymatter.nii.gz	GZ File	1,640 KB	No	1,683 KB	3%	05-10-2023 08:01
AD_13_greymatter.nii.gz	GZ File	1,639 KB	No	1,682 KB	3%	05-10-2023 08:01
AD_14_greymatter.nii.gz	GZ File	1,630 KB	No	1,670 KB	3%	05-10-2023 08:01
AD_15_greymatter.nii.gz	GZ File	1,565 KB	No	1,606 KB	3%	05-10-2023 08:01
AD_16_greymatter.nii.gz	GZ File	1,392 KB	No	1,436 KB	4%	05-10-2023 08:01
AD_17_greymatter.nii.gz	GZ File	1,669 KB	No	1,710 KB	3%	05-10-2023 08:01
AD_18_greymatter.nii.gz	GZ File	1,986 KB	No	2,026 KB	2%	05-10-2023 08:01
AD_19_greymatter.nii.gz	GZ File	2,019 KB	No	2,060 KB	2%	05-10-2023 08:01
AD_20_greymatter.nii.gz	GZ File	1,949 KB	No	1,990 KB	3%	05-10-2023 08:01
NC_01_greymatter.nii.gz	GZ File	801 KB	No	850 KB	6%	05-10-2023 08:04
NC_02_greymatter.nii.gz	GZ File	820 KB	No	872 KB	6%	05-10-2023 08:04
NC_03_greymatter.nii.gz	GZ File	1,029 KB	No	1,079 KB	5%	05-10-2023 08:04
NC_04_greymatter.nii.gz	GZ File	878 KB	No	931 KB	6%	05-10-2023 08:04
NC_05_greymatter.nii.gz	GZ File	865 KB	No	916 KB	6%	05-10-2023 08:04
NC_06_greymatter.nii.gz	GZ File	868 KB	No	917 KB	6%	05-10-2023 08:04
NC_07_greymatter.nii.gz	GZ File	1,072 KB	No	1,121 KB	5%	05-10-2023 08:04
NC_08_greymatter.nii.gz	GZ File	979 KB	No	1,028 KB	5%	05-10-2023 08:04
NC_09_greymatter.nii.gz	GZ File	967 KB	No	1,018 KB	5%	05-10-2023 08:04
NC_10_greymatter.nii.gz	GZ File	914 KB	No	964 KB	6%	05-10-2023 08:05
NC_11_greymatter.nii.gz	GZ File	941 KB	No	992 KB	6%	05-10-2023 08:05
NC_12_greymatter.nii.gz	GZ File	985 KB	No	1,035 KB	5%	05-10-2023 08:05
NC_13_greymatter.nii.gz	GZ File	889 KB	No	939 KB	6%	05-10-2023 08:06
NC_14_greymatter.nii.gz	GZ File	1,012 KB	No	1,063 KB	5%	05-10-2023 08:06

The csv created due to the script/file measurement -

AD01-AD10_data	Comma Separated Values So...	6 KB	No	11 KB	48%	05-10-2023 10:47
AD11-AD20_data	Comma Separated Values So...	6 KB	No	11 KB	48%	05-10-2023 12:27
AD21-NC25_data	Comma Separated Values So...	5 KB	No	11 KB	59%	05-10-2023 10:13
NC01-NC10_data	Comma Separated Values So...	3 KB	No	11 KB	76%	05-10-2023 13:05
NC11-NC20_data	Comma Separated Values So...	3 KB	No	11 KB	76%	05-10-2023 13:23

The results obtained from our research endeavors pertaining to classification (SVM):

```

64 from sklearn import svm
65 from sklearn.metrics import accuracy_score
66
67 ## Initialize the SVM classifier
68 svm_classifier = svm.SVC(kernel='linear', C=1)
69
70 ## Train the SVM model on the training data
71 svm_classifier.fit(X_train, y_train)
72
73 # Predict the labels for the test data
74 y_pred = svm_classifier.predict(X_test)
75 print("Predictions: ")
76 print(y_pred)
77 # Calculate the accuracy of the model
78 accuracy = accuracy_score(y_test, y_pred)
79
80 # Print the accuracy
81 print("Accuracy:", accuracy * 100)

```

Predictions:
[0 0 1 0 1 0 1 1 1 0]
Accuracy: 90.0

Image 1: screenshot of the output of the accuracy.

Accuracy refers to the proportion of correctly classified individuals inside our test dataset. It serves as a fundamental measure for evaluating the overall performance of our model. Our model achieved an accuracy of 0.90, correctly identifying 90% of the individuals in the test set.

Section 5: Analysis and Summary

In this section, an examination and evaluation of the findings will be conducted.

The primary subject of discourse is to the methodology for interpreting the results derived from our classification investigations. The ramifications of our findings are assessed in relation to the effectiveness of our machine learning model and its potential for early detection of Alzheimer's disease.

Section 5.1 Discussion

In this section, we delve into a comprehensive analysis of the outcomes of our study, shedding light on both the strengths and limitations of our methodology. Our aim is to provide a balanced perspective on the effectiveness of our approach and identify areas where improvements can be made for future research. Additionally, we examine the critical role played by the feature extraction and normalization processes in shaping the overall classification performance.

Strengths of Our Methodology

One of the notable strengths of our methodology is the successful integration of various techniques learned from Labs 1 and 2. By combining skull-stripping, tissue segmentation, registration, and feature measurement, we have developed a holistic approach for the analysis of T1-weighted MRI brain images. This approach enables us to extract valuable information from multiple regions of interest (ROIs) in the Automated Anatomical Labeling (AAL) atlas.

Furthermore, our utilization of Support Vector Machines (SVM) for binary classification demonstrates the efficiency of this well-established machine learning technique in distinguishing between Alzheimer's disease (AD) patients and normal controls. The 90% accuracy achieved by our model signifies its robustness and potential utility in early AD detection.

Limitations and Potential Sources of Error

While our methodology shows promise, it is essential to acknowledge its limitations and potential sources of error. Firstly, our study sample size was relatively small, with only 50 participants (40 in the training set and 10 in the test set). This limited dataset may not fully capture the heterogeneity present in AD patient populations, and therefore, generalizing our findings to larger, more diverse cohorts should be approached with caution.

Additionally, our methodology relies on the assumption that the selected ROIs from the AAL atlas are sufficient for accurate AD classification. It is crucial to recognize that AD is a complex neurodegenerative condition, and some regions of the brain may hold more diagnostic value than others. Future research should explore the inclusion of additional ROIs or advanced feature selection techniques to enhance the model's discriminative power.

Impact of Feature Extraction and Normalization

The feature extraction and normalization processes played a pivotal role in shaping the classification performance of our model. Extracting grey matter volume information from multiple ROIs allowed us to create informative feature representations. The normalization step, which standardized these features to have a mean of zero and a standard deviation of one, was essential for improving the overall performance of our SVM classifier. This normalization mitigated the influence of variable feature scales on the model's accuracy, resulting in the 90% classification accuracy achieved.

Conclusion

In conclusion, our study has made significant strides in the realm of Alzheimer's disease prediction through the fusion of brain imaging analysis and machine learning techniques. However, it is essential to recognize that our findings represent a preliminary step in the journey toward early AD diagnosis. To enhance the clinical utility of our approach, future research should expand the dataset to encompass a more extensive and diverse patient population. Moreover, the feature selection process should be refined, and the model's performance rigorously evaluated on larger datasets before it can be considered for real-world applications.

Our interdisciplinary approach, drawing from the insights gained in Labs 1 and 2, serves as a testament to the potential of collaborative efforts in tackling complex medical challenges. As we continue to refine our methodology and accumulate more data, we remain committed to advancing the early diagnosis of Alzheimer's disease and improving the lives of affected individuals.